Covid19 Pneumonia Clinical Trial
Official title:
Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia
To determinate feasibility, safety and outcome with convalescent plasma in patients with severe COVID-19 penumonia
COVID-19 convalescent plasma will be infused to patients with severe COVID-19 pneumonia to determine feasibility, safety and clinical outcome efficacy by survival at-28 days. Data will be compared with match control arm patients without plasma infusion ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04565379 -
Clinical Trial to Investigate the Efficacy and Safety of NuSepin® in COVID-19 Pneumonia Patients
|
Phase 2 | |
| Recruiting |
NCT04527224 -
Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03183570 -
Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT
|
Early Phase 1 | |
| Recruiting |
NCT04642040 -
Effectiveness of Pulmonary Rehabilitation Program in Patients With SARS-CoV-2 Pneumonia
|
N/A | |
| Recruiting |
NCT04487951 -
N-terminal Pro B-type Natriuretic Peptide and Vitamin D Levels as Prognostic Markers in COVID-19 Pneumonia
|
||
| Active, not recruiting |
NCT04881214 -
COVID-19 Pneumonia: Pulmonary Physiology, Health-related Quality of Life and Benefit of a Rehabilitation Program
|
N/A | |
| Recruiting |
NCT04377750 -
The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation
|
Phase 4 | |
| Recruiting |
NCT04569227 -
Prevention of COVID-19 Infection to Severe Pneumonia or ARDS
|
Phase 2 | |
| Not yet recruiting |
NCT04344756 -
Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort
|
Phase 2 | |
| Not yet recruiting |
NCT04344782 -
Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin®/Zeribev®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort
|
Phase 2 |